JP2020520917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520917A5 JP2020520917A5 JP2019563463A JP2019563463A JP2020520917A5 JP 2020520917 A5 JP2020520917 A5 JP 2020520917A5 JP 2019563463 A JP2019563463 A JP 2019563463A JP 2019563463 A JP2019563463 A JP 2019563463A JP 2020520917 A5 JP2020520917 A5 JP 2020520917A5
- Authority
- JP
- Japan
- Prior art keywords
- positively charged
- gly
- botulinum toxin
- pharmaceutical composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 108030001720 Bontoxilysin Proteins 0.000 claims 16
- 229940053031 botulinum toxin Drugs 0.000 claims 16
- 230000000694 effects Effects 0.000 claims 7
- 108010039918 Polylysine Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229920000656 polylysine Polymers 0.000 claims 6
- 206010044074 Torticollis Diseases 0.000 claims 4
- 201000002866 cervical dystonia Diseases 0.000 claims 4
- 238000011287 therapeutic dose Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007972 injectable composition Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508324P | 2017-05-18 | 2017-05-18 | |
| US62/508,324 | 2017-05-18 | ||
| PCT/US2018/033397 WO2018213710A1 (en) | 2017-05-18 | 2018-05-18 | Methods of treatment for cervical dystonia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520917A JP2020520917A (ja) | 2020-07-16 |
| JP2020520917A5 true JP2020520917A5 (enExample) | 2021-07-26 |
Family
ID=64274745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563463A Pending JP2020520917A (ja) | 2017-05-18 | 2018-05-18 | 頸部ジストニアの治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200179498A1 (enExample) |
| EP (1) | EP3624819A4 (enExample) |
| JP (1) | JP2020520917A (enExample) |
| KR (2) | KR20250037595A (enExample) |
| CN (1) | CN110996979A (enExample) |
| AU (2) | AU2018270092B2 (enExample) |
| BR (1) | BR112019024082A2 (enExample) |
| CA (1) | CA3064070A1 (enExample) |
| CO (1) | CO2019014212A2 (enExample) |
| MX (1) | MX2019013716A (enExample) |
| PH (1) | PH12019502578A1 (enExample) |
| RU (1) | RU2019141383A (enExample) |
| WO (1) | WO2018213710A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX365496B (es) * | 2009-10-21 | 2019-06-05 | Revance Therapeutics Inc | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
| US12161703B2 (en) | 2017-08-28 | 2024-12-10 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
| WO2022081736A1 (en) * | 2020-10-13 | 2022-04-21 | Revance Therapeutics, Inc. | Methods for treating cervical dystonia |
| CN117693366A (zh) * | 2021-02-21 | 2024-03-12 | 雷文斯治疗公司 | 用于治疗上肢痉挛的方法和组合物 |
| WO2025059665A1 (en) | 2023-09-15 | 2025-03-20 | Revance Therapeutics, Inc. | Serial treatment with botulinum toxin for cervical dystonia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557256B2 (en) * | 1993-12-28 | 2013-10-15 | Allergan, Inc. | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| HUE025656T2 (en) * | 2004-03-03 | 2016-04-28 | Revance Therapeutics Inc | Topical application of botulotoxins and transdermal delivery |
| SG10201405582YA (en) | 2008-12-31 | 2014-10-30 | Revance Therapeutics Inc | Injectable Botulinum Toxin Formulations |
| KR102192618B1 (ko) * | 2009-06-25 | 2020-12-17 | 레반스 테라퓨틱스, 아이엔씨. | 알부민불포함 보툴리눔 독소 제제 |
| US8147848B2 (en) * | 2009-08-26 | 2012-04-03 | Allergan, Inc. | Method for treating premature ejaculation with a botulinum neurotoxin |
| PL2661276T3 (pl) * | 2011-01-07 | 2018-03-30 | Revance Therapeutics, Inc. | Kompozycja do stosowania miejscowego zawierająca toksynę bakterii botulinowych i barwnik |
| RU2014103543A (ru) * | 2011-07-20 | 2015-08-27 | Аллерган, Инк. | Ботулотоксины для применения в способе лечения жировых отложений |
| JP6955491B2 (ja) | 2015-10-29 | 2021-10-27 | ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法 |
| AU2018359962A1 (en) * | 2017-11-03 | 2020-05-28 | Revance Therapeutics, Inc. | Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect |
| EP3720475A4 (en) * | 2017-12-04 | 2021-09-08 | ReVance Therapeutics, Inc. | BOTULINUM TOXIN INJECTABLE FORMULATIONS AND METHODS OF USE THEREOF WITH A HIGH RESPONSE RATE AND LONG-LASTING EFFECT |
| RU2741221C1 (ru) | 2020-04-30 | 2021-01-22 | Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" (ФГАОУ ВО "КФУ им. В.И. Вернадского") | Способ комплексной реабилитации двигательной функции верхней конечности у больных детским церебральным параличом |
-
2018
- 2018-05-18 BR BR112019024082-9A patent/BR112019024082A2/pt unknown
- 2018-05-18 EP EP18802488.9A patent/EP3624819A4/en active Pending
- 2018-05-18 KR KR1020257007090A patent/KR20250037595A/ko active Pending
- 2018-05-18 RU RU2019141383A patent/RU2019141383A/ru unknown
- 2018-05-18 WO PCT/US2018/033397 patent/WO2018213710A1/en not_active Ceased
- 2018-05-18 CA CA3064070A patent/CA3064070A1/en active Pending
- 2018-05-18 JP JP2019563463A patent/JP2020520917A/ja active Pending
- 2018-05-18 MX MX2019013716A patent/MX2019013716A/es unknown
- 2018-05-18 AU AU2018270092A patent/AU2018270092B2/en active Active
- 2018-05-18 KR KR1020197037005A patent/KR102777928B1/ko active Active
- 2018-05-18 US US16/614,773 patent/US20200179498A1/en not_active Abandoned
- 2018-05-18 CN CN201880042201.4A patent/CN110996979A/zh active Pending
-
2019
- 2019-11-18 PH PH12019502578A patent/PH12019502578A1/en unknown
- 2019-12-16 CO CONC2019/0014212A patent/CO2019014212A2/es unknown
-
2021
- 2021-12-09 US US17/547,211 patent/US12257293B2/en active Active
-
2025
- 2025-03-24 US US19/088,478 patent/US20250319168A1/en active Pending
- 2025-07-16 AU AU2025205532A patent/AU2025205532A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520917A5 (enExample) | ||
| Mankovskaia et al. | Catechin-incorporated dental copolymers inhibit growth of Streptococcus mutans | |
| JP2012532185A5 (enExample) | ||
| HRP20191852T1 (hr) | Polipeptidi | |
| RU2013108248A (ru) | Иммуногенные противовоспалительные композиции | |
| JP2018531984A5 (enExample) | ||
| JP2018522563A5 (enExample) | ||
| JP2017523985A5 (enExample) | ||
| JP2015518818A5 (enExample) | ||
| JP2019520841A5 (enExample) | ||
| JP2012176978A5 (enExample) | ||
| JP2014502628A5 (enExample) | ||
| JP2015529685A5 (enExample) | ||
| JP2016518442A5 (enExample) | ||
| JP2015510393A5 (enExample) | ||
| RU2019141383A (ru) | Способы лечения цервикальной дистонии | |
| JP2014529399A5 (enExample) | ||
| JP2017512194A5 (enExample) | ||
| JP2014532722A5 (enExample) | ||
| JP2018531880A5 (enExample) | ||
| RU2015106742A (ru) | Композиции, содержащие химерные молекулы ospa и способы их применения | |
| JP2015524802A5 (enExample) | ||
| RU2014124171A (ru) | Лекарственное средство для терапевтического лечения и/или улучшения состояния при сепсисе | |
| JP2018100243A5 (enExample) | ||
| JP2016512247A5 (enExample) |